{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:53:23Z","timestamp":1764510803417,"version":"3.37.3"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"DOI":"10.1182\/bloodadvances.2022008031","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T17:06:46Z","timestamp":1658941606000},"page":"375-378","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-4346","authenticated-orcid":false,"given":"Khoan","family":"Vu","sequence":"first","affiliation":[{"name":"1Department of Oncology\/Hematology, Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3354","authenticated-orcid":false,"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"2Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"issue":"14","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Eng J Med"},{"issue":"10299","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10297","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a\u00a0B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a\u00a0single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16_suppl","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"e19583","DOI":"10.1200\/JCO.2022.40.16_suppl.e19583","article-title":"Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real-world experience from the United States lymphoma CAR T consortium","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"2023021422371116500_","unstructured":"National Comprehensive Cancer Network . B-Cell Lymphomas (Version 4) 2022. Accessed 28 June 2022https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"11","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3109\/10428194.2013.767454","article-title":"Risk factors of central nervous system relapse in mantle cell lymphoma","volume":"54","author":"Conconi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study\u00a0by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"13","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study\u00a0Association (LYSA)\u2020","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"key":"2023021422371116500_","unstructured":"Rusconi C , CheahC, TuckerD, . Ibrutinib compared to immuno-chemotherapy for central nervous system relapse of mantle cell lymphoma: a report from Fondazione Italiana Linfomi (FIL) and European Mantle Cell Lymphoma Network (EMCLN). [Abstract.]. Eur Hematol Assoc. Accessed 22 February 2022. Published online 2020https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/295049\/chiara.rusconi.ibrutinib.compared.to.immuno-chemotherapy.for.central.nervous.html?f=menu=6."},{"issue":"3","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in\u00a0clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2023021422371116500_","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/375\/2033422\/blooda_adv-2022-008031-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/375\/2033422\/blooda_adv-2022-008031-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T01:21:13Z","timestamp":1700875273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/375\/486032\/CAR-T-cell-therapy-for-mantle-cell-lymphoma-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008031","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}